Anti-VEGF therapy: The search for clinical biomarkers

Raffaele Longo, Giampietro Gasparini

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Despite the large diffusion and rapid development of anti-VEGF therapy in clinical practice and in contrast to the consolidated evidence with imatinib and trastuzumab that demonstrated a direct correlation between pre-treatment target expression and drug activity, it is very difficult, at present, to identify validated and useful biomarkers to monitor the efficacy of these compounds and to appropriately select patients most likely to benefit from such treatments. However, emerging data suggest that this is not presently feasible for antiangiogenic drugs. Although tumoral and/or circulating VEGF levels have been associated with tumor progression and/or poor prognosis, to date, there is no validated evidence suggesting their role as potential predictive biomarkers of response to anti-VEGF therapy. Recently, many studies have documented promising results with the evaluation of circulating endothelial cells and/or progenitors, and the use of several imaging techniques, such as dynamic contrast-enhanced MRI, PET, dynamic CT scan and functional ultrasound. These preliminary data need a validation in larger prospective trials.

Original languageEnglish
Pages (from-to)301-314
Number of pages14
JournalExpert Review of Molecular Diagnostics
Volume8
Issue number3
DOIs
Publication statusPublished - May 2008

Fingerprint

Vascular Endothelial Growth Factor A
Biomarkers
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Angiogenesis
  • Bevacizumab
  • Sorafenib
  • Sunitinib
  • Vatalanib
  • VEGF

ASJC Scopus subject areas

  • Genetics

Cite this

Anti-VEGF therapy : The search for clinical biomarkers. / Longo, Raffaele; Gasparini, Giampietro.

In: Expert Review of Molecular Diagnostics, Vol. 8, No. 3, 05.2008, p. 301-314.

Research output: Contribution to journalArticle

Longo, Raffaele ; Gasparini, Giampietro. / Anti-VEGF therapy : The search for clinical biomarkers. In: Expert Review of Molecular Diagnostics. 2008 ; Vol. 8, No. 3. pp. 301-314.
@article{2894264be98e428995cc6c1380e9b604,
title = "Anti-VEGF therapy: The search for clinical biomarkers",
abstract = "Despite the large diffusion and rapid development of anti-VEGF therapy in clinical practice and in contrast to the consolidated evidence with imatinib and trastuzumab that demonstrated a direct correlation between pre-treatment target expression and drug activity, it is very difficult, at present, to identify validated and useful biomarkers to monitor the efficacy of these compounds and to appropriately select patients most likely to benefit from such treatments. However, emerging data suggest that this is not presently feasible for antiangiogenic drugs. Although tumoral and/or circulating VEGF levels have been associated with tumor progression and/or poor prognosis, to date, there is no validated evidence suggesting their role as potential predictive biomarkers of response to anti-VEGF therapy. Recently, many studies have documented promising results with the evaluation of circulating endothelial cells and/or progenitors, and the use of several imaging techniques, such as dynamic contrast-enhanced MRI, PET, dynamic CT scan and functional ultrasound. These preliminary data need a validation in larger prospective trials.",
keywords = "Angiogenesis, Bevacizumab, Sorafenib, Sunitinib, Vatalanib, VEGF",
author = "Raffaele Longo and Giampietro Gasparini",
year = "2008",
month = "5",
doi = "10.1586/14737159.8.3.301",
language = "English",
volume = "8",
pages = "301--314",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Anti-VEGF therapy

T2 - The search for clinical biomarkers

AU - Longo, Raffaele

AU - Gasparini, Giampietro

PY - 2008/5

Y1 - 2008/5

N2 - Despite the large diffusion and rapid development of anti-VEGF therapy in clinical practice and in contrast to the consolidated evidence with imatinib and trastuzumab that demonstrated a direct correlation between pre-treatment target expression and drug activity, it is very difficult, at present, to identify validated and useful biomarkers to monitor the efficacy of these compounds and to appropriately select patients most likely to benefit from such treatments. However, emerging data suggest that this is not presently feasible for antiangiogenic drugs. Although tumoral and/or circulating VEGF levels have been associated with tumor progression and/or poor prognosis, to date, there is no validated evidence suggesting their role as potential predictive biomarkers of response to anti-VEGF therapy. Recently, many studies have documented promising results with the evaluation of circulating endothelial cells and/or progenitors, and the use of several imaging techniques, such as dynamic contrast-enhanced MRI, PET, dynamic CT scan and functional ultrasound. These preliminary data need a validation in larger prospective trials.

AB - Despite the large diffusion and rapid development of anti-VEGF therapy in clinical practice and in contrast to the consolidated evidence with imatinib and trastuzumab that demonstrated a direct correlation between pre-treatment target expression and drug activity, it is very difficult, at present, to identify validated and useful biomarkers to monitor the efficacy of these compounds and to appropriately select patients most likely to benefit from such treatments. However, emerging data suggest that this is not presently feasible for antiangiogenic drugs. Although tumoral and/or circulating VEGF levels have been associated with tumor progression and/or poor prognosis, to date, there is no validated evidence suggesting their role as potential predictive biomarkers of response to anti-VEGF therapy. Recently, many studies have documented promising results with the evaluation of circulating endothelial cells and/or progenitors, and the use of several imaging techniques, such as dynamic contrast-enhanced MRI, PET, dynamic CT scan and functional ultrasound. These preliminary data need a validation in larger prospective trials.

KW - Angiogenesis

KW - Bevacizumab

KW - Sorafenib

KW - Sunitinib

KW - Vatalanib

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=44249108138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44249108138&partnerID=8YFLogxK

U2 - 10.1586/14737159.8.3.301

DO - 10.1586/14737159.8.3.301

M3 - Article

C2 - 18598109

AN - SCOPUS:44249108138

VL - 8

SP - 301

EP - 314

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 3

ER -